GIGABYTE
3.1.2022 07:05:09 CET | Business Wire | Press release
GIGABYTE is joining CES Virtual with its website extension – INDUSTRY – to present products and solutions that propel digital transformation in industries such as 5G & telecom, automotive, creative & gaming, data centers , manufacturing, and retail.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211229005431/en/
GIGABYTE takes pride in having an incredibly deep portfolio of enterprise products that support cloud, edge, and data centers. There are over 75 servers for AMD EPYC CPU alone, as well as Intel Xeon Scalable CPU, and over 10 servers for Ampere Altra CPU, and not to forget over 20 server motherboards. GIGABYTE offers edge servers developed based on Arm architecture. These high-density Arm servers , using Ampere’s massive 80 / 128 core CPU, provide the performance, storage, network, and above all, the flexibility to be deployed for the next generation of telecommunications where processing work needs to be done on-site. GIGABYTE’s server solutions are also applicable to various industries, and are highly valued by large and small high-tech companies, medical, scientific, academic research, and public institutions, etc., and have successfully assisted them in innovation and breakthroughs in their fields.
Our industries are undergoing an invigorating metamorphosis as AI, HPC, IoT, and other breakthroughs bring about a paradigm shift. MyelinTek Inc., an investee company of GIGABYTE developed a deep learning system MLSteam, which includes optimized AI software stacking and comprehensive management tools in a user-friendly interface to make it easier for scientists to train and develop AI integration for autonomous vehicles. With the rapid development of Advanced Driver Assistance Systems (ADAS ) technology, GIGABYTE designs decision-making control units for different types of autonomous vehicles, as well as customized products such as ADAS ECUs, TCUs, assisting vehicles designers to develop their ideal products and improve the automotive industry.
GIGABYTE has years of proven experience in embedded computers and brought its latest generation of embedded systems to increase the operability of storage, logistic, and manufacturing facilities while lowering labor and management costs with the innovation of AGV, AMR, and Industrial Automation Security System. In the post-pandemic era, GIGABYTE’s embedded solutions integrated with AI and IoT technology helped automate the operation and management of open space rentals, allowing such new services to flourish.
GIGABYTE’s reputation to invent top-notch products with innovative VRM and thermal design makes the task to optimize overclocking performance on the latest Intel® Core™ CPUs easy and effective. The Z690 series motherboards provide beyond the essential features and power for both professional creators and gamers alike. Performance is the key to both immersive gameplay and smooth workflow, and GIGABYTE has taken performance above all else with this generation’s AORUS gaming laptops and the AERO creator laptops which are to be released in early 2022.
GIGABYTE has recently launched INDUSTRY to demonstrate its most pivotal products and solutions for different industries. One of the biggest highlights of the platform is its live chat function. GIGABYTE has arranged experts, who have keen insights on the industries, to standby the live chat and answer questions and inquiries made by CES visitors and buyers as they would at the physical venue. The live chat uses AI-generated avatars to show the status of its live experts, and also as a way to embrace the ‘metaverse ’ where virtual merges with reality. The INDUSTRY platform will host all products and solutions GIGABYTE is presenting at CES including trendy topics highlighted in the event and more. GIGABYTE welcomes all visitors to connect through this digital platform and see their industries from different perspectives.
INDUSTRY: https://industry.gigabyte.com
Visit GIGABYTE on CES Digital: https://gbte.tech/ces2022
View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005431/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom